Home › Funds › Aisling Capital Management LP › URGN
Aisling Capital Management LP position in URGN
UROGEN PHARMA LTD · Health Care
Aisling Capital Management LP reported holding 108,000 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 1.47% of its reported portfolio and ranking #6 among its reported holdings. Aisling Capital Management LP has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aisling Capital Management LP's URGN position evolved
Aisling Capital Management LP first disclosed a stake in URGN in Q4 2025 at 108,000 shares (US$2.5M). The position peaked in Q3 2026 at 108,000 shares, worth US$4.4M. Across 4 filings, Aisling Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 108,000 shares valued at US$4.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 108.00K | $2.53M | New |
| Q1 2026 | 108.00K | $1.94M | Hold |
| Q2 2026 | 108.00K | $3.97M | Hold |
| Q3 2026 | 108.00K | $4.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 45 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M sh · $89.37M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.15M sh · $46.67M · Q3 2026
- MPM BioImpact LLC 933.41K sh · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K sh · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- NEXT CENTURY GROWTH INVESTORS LLC 297.08K sh · $12.07M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on Aisling Capital Management LP
FAQ
How long has Aisling Capital Management LP held URGN?
Aisling Capital Management LP has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Aisling Capital Management LP's current position in URGN?
As of Q3 2026, Aisling Capital Management LP holds 108.00K shares of URGN (UROGEN PHARMA LTD), valued at $4.39M, representing 1.47% of its reported portfolio and ranking #6.
Has Aisling Capital Management LP been buying or selling URGN?
In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in URGN. The position peaked in Q3 2026 at 108.00K shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.